Published in Hepatitis Weekly, August 16th, 1999
"Cirrhotic and fibrotic patients with chronic hepatitis C virus (HCV) benefit from treatment with interferon to the same degree as nonfibrotic patients if one assesses efficacy by clearance of serum HCV RNA," researcher Gregory T. Everson and colleagues wrote ("Efficacy of Interferon Treatment for Patients with Chronic Hepatitis C: Comparison of Response in Cirrhotics, Fibrotics, and Nonfibrotics," Hepatology, July 1999;30(1):271-276).
Morbidity and mortality in chronic HCV infection is primarily associated with decompensated liver...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.